LUPIN Financial Statement Analysis
|
||
|
The Revenues of LUPIN have increased by 1.44% YoY .
The Earnings Per Share (EPS) of LUPIN has increased by Positive YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
LUPIN Last 5 Annual Financial Results
[BOM: 500257|NSE : LUPIN]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹16,642 Cr | ₹16,405 Cr | ₹15,163 Cr | ₹15,375 Cr | ₹14,665 Cr |
| Expenses | ₹14,921 Cr | ₹16,190 Cr | ₹12,596 Cr | ₹13,020 Cr | ₹12,104 Cr |
| Operating Profit (Excl OI) | ₹1,721 Cr | ₹215 Cr | ₹2,567 Cr | ₹2,355 Cr | ₹2,561 Cr |
| Other Income | ₹151 Cr | ₹214 Cr | ₹136 Cr | ₹484 Cr | ₹333 Cr |
| Interest | ₹274 Cr | ₹143 Cr | ₹141 Cr | ₹363 Cr | ₹302 Cr |
| Depreciation | ₹881 Cr | ₹1,659 Cr | ₹887 Cr | ₹970 Cr | ₹846 Cr |
| Profit Before Tax | ₹716 Cr | ₹-1,372 Cr | ₹1,676 Cr | ₹757 Cr | ₹1,409 Cr |
| Profit After Tax | ₹448 Cr | ₹-1,509 Cr | ₹1,228 Cr | ₹-400 Cr | ₹521 Cr |
| Consolidated Net Profit | ₹430 Cr | ₹-1,528 Cr | ₹1,217 Cr | ₹-269 Cr | ₹607 Cr |
| Earnings Per Share (Rs) | ₹9.45 | ₹-33.62 | ₹26.81 | ₹-5.95 | ₹13.40 |
| PAT Margin (%) | 1.57 | -5.09 | 4.34 | -1.34 | 1.97 |
| ROE(%) | 3.68 | -11.79 | 9.47 | -3.09 | 3.88 |
| ROCE(%) | 6.06 | -7.11 | 9.71 | 5.45 | 7.97 |
| Total Debt/Equity(x) | 0.34 | 0.32 | 0.35 | 0.51 | 0.63 |
Key Financials |
||
| Market Cap | : | ₹ 74,999.6 Cr |
| Revenue (TTM) | : | ₹ 19,480.1 Cr |
| Net Profit(TTM) | : | ₹ 1,809.7 Cr |
| EPS (TTM) | : | ₹ 39.7 |
| P/E (TTM) | : | 41.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LUPIN | 4.1% | 3% | 131.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.1% | -6.6% | 56.7% |
| CIPLA | 0.2% | -4.4% | 54.3% |
| DR REDDYS LABORATORIES | 4.3% | 2.6% | 29.9% |
| ZYDUS LIFESCIENCES | 2.2% | -4.6% | 86.6% |
| DIVIS LABORATORIES | 4.8% | 18.9% | 23.9% |
| MANKIND PHARMA | -1.4% | 1.4% | NA |
| TORRENT PHARMACEUTICALS | -1.7% | 3% | 65.8% |
| AUROBINDO PHARMA | 6.4% | 7.7% | 87.6% |
LUPIN Revenues
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 1.44 % |
| 5 Yr CAGR | 3.21 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹16,642 Cr | 1.44 | |
| Mar2022 | ₹16,405 Cr | 8.19 | |
| Mar2021 | ₹15,163 Cr | -1.38 | |
| Mar2020 | ₹15,375 Cr | 4.84 | |
| Mar2019 | ₹14,665 Cr | - | |
LUPIN Operating Profit
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 699.37 % |
| 5 Yr CAGR | -9.46 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,721 Cr | 699.37 | |
| Mar2022 | ₹215 Cr | -91.61 | |
| Mar2021 | ₹2,567 Cr | 9.01 | |
| Mar2020 | ₹2,355 Cr | -8.04 | |
| Mar2019 | ₹2,561 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 689.31 % |
| 5 Yr CAGR | -12.28 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 10.34% | 689.31 | |
| Mar2022 | 1.31% | -92.26 | |
| Mar2021 | 16.93% | 10.51 | |
| Mar2020 | 15.32% | -12.26 | |
| Mar2019 | 17.46% | - | |
LUPIN Profit After Tax
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | Positive |
| 5 Yr CAGR | -8.24 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹430 Cr | Positive | |
| Mar2022 | ₹-1,528 Cr | Negative | |
| Mar2021 | ₹1,217 Cr | Positive | |
| Mar2020 | ₹-269 Cr | Negative | |
| Mar2019 | ₹607 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Positive |
| 5 Yr CAGR | -5.52 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 1.57 % | Positive | |
| Mar2022 | -5.09 % | Negative | |
| Mar2021 | 4.34 % | Positive | |
| Mar2020 | -1.34 % | Negative | |
| Mar2019 | 1.97 % | - | |
LUPIN Earnings Per Share (EPS)
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | Positive |
| 5 Yr CAGR | -8.36 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹9.45 | Positive | |
| Mar2022 | ₹-34 | Negative | |
| Mar2021 | ₹27 | Positive | |
| Mar2020 | ₹-5.95 | Negative | |
| Mar2019 | ₹13 | - | |
LUPIN Return on Capital Employed (ROCE)
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | Positive |
| 5 Yr CAGR | -6.62 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 6.06% | Positive | |
| Mar2022 | -7.11% | Negative | |
| Mar2021 | 9.71% | 78.17 | |
| Mar2020 | 5.45% | -31.62 | |
| Mar2019 | 7.97% | - | |
LUPIN Share Price vs Sensex
| Current Share Price | : | ₹1,645.5 |
| Current MarketCap | : | ₹ 74,999.6 Cr |
| Updated EOD on | : | Apr 30,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LUPIN | 4.1% |
3% |
131.2% |
| SENSEX | 1% |
2.8% |
23.9% |
LUPIN related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MIDCAP SELECT INDEX | 4.5% | 6.1% | 63.2% |
| S&P BSE MOMENTUM | 4.3% | 8% | 83.3% |
| S&P BSE MID CAP | 3.8% | 7.8% | 68.7% |
| S&P BSE 150 MIDCAP | 3.3% | 7.5% | 60.9% |
| S&P BSE SENSEX NEXT 50 | 3% | 6.8% | 58.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY200 MOMENTUM 30 INDEX | 4.4% | 6.8% | 71.9% |
| NIFTY HEALTHCARE | 2.9% | 0.7% | 52.1% |
| NIFTY MIDCAP 50 | 2.8% | 5.1% | 60.7% |
| NIFTY PHARMA | 2.8% | 0.9% | 52.3% |
| NIFTY MIDCAP150 | 2.6% | 7% | 61.1% |
You may also like the below Video Courses
FAQ about LUPIN Financials
How the annual revenues of LUPIN have changed ?
The Revenues of LUPIN have increased by 1.44% YoY .
How the Earnings per Share (EPS) of LUPIN have changed?
The Earnings Per Share (EPS) of LUPIN has increased by Positive YoY .
Check out Intrinsic Value of Peers of LUPIN
Compare Stock Analytics of Peers of LUPIN
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
